|Bid||151.21 x 800|
|Ask||151.31 x 800|
|Day's Range||150.26 - 153.76|
|52 Week Range||115.03 - 217.25|
|Beta (5Y Monthly)||1.70|
|PE Ratio (TTM)||7.58|
|Earnings Date||May 02, 2023 - May 08, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||226.64|
Subscribe to Yahoo Finance Plus to view Fair Value for MRNA
Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss Moderna CEO Stephane Bancel’s testimony before the U.S. Senate health committee.
Moderna Inc has entered a licensing deal with Generation Bio Co to develop treatments targeting the immune system and liver, the latest such transaction by the vaccine maker as it expands beyond its COVID shots. Generation Bio's shares rose about 13.14% to $4.40 in premarket trading on Thursday. Moderna will pay $40 million in cash upfront, and make a $36 million equity investment in Cambridge, Massachusetts-based Generation Bio.
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Generation Bio Co.